JP2024532886A5 - - Google Patents

Info

Publication number
JP2024532886A5
JP2024532886A5 JP2024512952A JP2024512952A JP2024532886A5 JP 2024532886 A5 JP2024532886 A5 JP 2024532886A5 JP 2024512952 A JP2024512952 A JP 2024512952A JP 2024512952 A JP2024512952 A JP 2024512952A JP 2024532886 A5 JP2024532886 A5 JP 2024532886A5
Authority
JP
Japan
Application number
JP2024512952A
Other languages
Japanese (ja)
Other versions
JP2024532886A (ja
JPWO2023025215A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/114642 external-priority patent/WO2023025215A1/en
Publication of JP2024532886A publication Critical patent/JP2024532886A/ja
Publication of JP2024532886A5 publication Critical patent/JP2024532886A5/ja
Publication of JPWO2023025215A5 publication Critical patent/JPWO2023025215A5/ja
Pending legal-status Critical Current

Links

JP2024512952A 2021-08-25 2022-08-25 ヒトＣＤ１６ａに対する抗体及びその変異体 Pending JP2024532886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021114549 2021-08-25
CNPCT/CN2021/114549 2021-08-25
PCT/CN2022/114642 WO2023025215A1 (en) 2021-08-25 2022-08-25 ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a

Publications (3)

Publication Number Publication Date
JP2024532886A JP2024532886A (ja) 2024-09-10
JP2024532886A5 true JP2024532886A5 (https=) 2025-09-01
JPWO2023025215A5 JPWO2023025215A5 (https=) 2025-09-01

Family

ID=85321557

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512952A Pending JP2024532886A (ja) 2021-08-25 2022-08-25 ヒトＣＤ１６ａに対する抗体及びその変異体

Country Status (6)

Country Link
US (1) US20240352128A1 (https=)
EP (1) EP4392453A4 (https=)
JP (1) JP2024532886A (https=)
KR (1) KR20240049331A (https=)
CN (1) CN117858902A (https=)
WO (1) WO2023025215A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120813603A (zh) * 2023-03-03 2025-10-17 广州百济神州生物制药有限公司 Cd16a抗体和使用方法
KR20250156802A (ko) * 2023-03-03 2025-11-03 비원 메디슨즈 아이 게엠베하 Muc1 및 cd16a 항체 및 사용 방법
WO2024206126A1 (en) * 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
CN120025439B (zh) * 2023-11-21 2026-04-17 南京融捷康生物科技有限公司 一种抗CD16a的单域抗体及其用途
CN118221818B (zh) * 2024-04-29 2025-01-24 四川大学 一种抗cd16a的纳米抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334453D1 (de) * 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US20070036786A1 (en) * 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
WO2018039626A1 (en) * 2016-08-25 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human single domain antibodies targeting cd16a to mediate adcc
CN110461357A (zh) * 2017-02-28 2019-11-15 阿菲姆德股份有限公司 抗cd16a抗体与细胞因子的组合
WO2022161314A1 (zh) * 2021-01-27 2022-08-04 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途

Similar Documents

Publication Publication Date Title
JP2024532886A5 (https=)
CL2025003930A1 (es) Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradadores de smarca2 para el tratamiento del cáncer.
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022001779U2 (https=)
BY13168U (https=)
BY13162U (https=)
CN307046245S (https=)
CN307045323S (https=)
CN307044735S (https=)
CN307044684S (https=)
CN307044679S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)
CN307048403S (https=)